HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
Deals

Cardio drug developer Esperion to go private in potential $1.1B buyout by ArchiMed

Shortly after laying out $75 million upfront for Corstasis Therapeutics and its congestive heart failure edema drug Enbumyst, Esperion Therapeutics is itself being acquired and taken private by healthcare investment firm ArchMmed.

By FiercePharma · May 2, 2026 · via FiercePharma
Cardio drug developer Esperion to go private in potential $1.1B buyout by ArchiMed

Image: FiercePharma

This is an aggregated industry headline. Read the full story at FiercePharma →

Tags
dealsformat:headlineheadlineFiercePharma
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from Deals
All Deals →
Teva inks $700M Emalex buyout to bag near-approval Tourette drug
DealsFierceBiotech ↗
Teva inks $700M Emalex buyout to bag near-approval Tourette drug
Teva Pharmaceuticals has struck a deal to buy Emalex Biosciences for $700 million upfront, positioning the dru…
May 1, 2026
AstraZeneca Reverses UK Freeze with £300M Restart, Merck Still Holding Out
DealsBriefing
AstraZeneca Reverses UK Freeze with £300M Restart, Merck Still Holding Out
AstraZeneca resumes its shelved £300M UK expansion after rebate relief and a U.S.-U.K. pharma pact, signaling …
May 1, 2026
AbbVie dips into boiling RAS waters with $1.45B biobucks deal that could end in acquisition
DealsFierceBiotech ↗
AbbVie dips into boiling RAS waters with $1.45B biobucks deal that could end in acquisition
AbbVie has agreed to help finance a KRAS inhibitor from Kestrel Therapeutics in a deal that could hit up to $1…
May 1, 2026